AB
INKT icon

Amalgamated Bank’s MiNK Therapeutics INKT Stock Holding History

Amalgamated Bank’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30
Closed -$1K – 3117
2022
Q1 		$1K Buy
+30
New +$901 ﹤0.01% 3057

Other funds holding INKT

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Amalgamated Bank's INKT Position: Q2 2022 in Review

Amalgamated Bank sold out of MiNK Therapeutics (INKT) in Q2 2022, closing a stake of 30 shares — an estimated $1K sold.

Amalgamated Bank first reported a position in INKT in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 11 funds tracked by Wall St. Rank hold INKT as of Q2 2022.

  • Amalgamated Bank reported no remaining MiNK Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Amalgamated Bank sold 30 MiNK Therapeutics shares in Q2 2022, an estimated $1K.
  • Amalgamated Bank first reported a position in MiNK Therapeutics in Q1 2022 and held it in 1 quarter.
  • Amalgamated Bank's MiNK Therapeutics position peaked at $1K in Q1 2022.
  • 11 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q2 2022.

Based on Amalgamated Bank's 13F filing for Q2 2022, filed 15 Aug 2022.